SpringWorks Therapeutics, Inc. (SWTX) Dividend History

Company News

• $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL

  Monteverde & Associates PC, a top 50 class action law firm, is investigating the proposed mergers of ProAssurance Corporation, American Axle & Manufacturing Holdings, SpringWorks Therapeutics, and Vigil Neuroscience. The firm is encouraging shareholders to take action and learn more about the proposed transactions.

  GlobeNewswire Inc.

  Featured Companies: AXL PRA VIGL
• $HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The Merger - PRA, AXL, SWTX and VIGL

  The M&A Class Action Firm is investigating the proposed mergers of ProAssurance Corporation, American Axle & Manufacturing Holdings, SpringWorks Therapeutics, and Vigil Neuroscience.

  Benzinga

  Featured Companies: AXL PRA VIGL
• SpringWorks Therapeutics: CHMP valuta positivamente Mirdametinib per il trattamento di pazienti adulti e pediatrici affetti da NF1-PN

  SpringWorks Therapeutics announced that the European Medicines Agency's CHMP has issued a positive opinion for the approval of mirdametinib to treat adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). If approved, mirdametinib would be the first and only therapy in the EU with marketing authorization for both adults and children with NF1-PN.

  GlobeNewswire Inc.
• SpringWorks Therapeutics recibe un dictamen positivo del CHMP para el uso de mirdametinib en el tratamiento de la NF1-NP en pacientes adultos y pediátricos

  SpringWorks Therapeutics received a positive opinion from the CHMP for the use of mirdametinib in the treatment of NF1-PN in adult and pediatric patients. If approved, mirdametinib would be the first and only therapy authorized for NF1-PN in the European Union for both adults and children.

  GlobeNewswire Inc.
• SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN

  SpringWorks Therapeutics received a positive opinion from the CHMP of the EMA for the use of mirdametinib to treat adult and pediatric patients with NF1-PN. If approved, mirdametinib would be the first and only therapy in the EU with marketing authorization for both adults and children with NF1-PN.

  GlobeNewswire Inc.